{"id":3652,"date":"2016-05-23T23:54:58","date_gmt":"2016-05-23T23:54:58","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3652"},"modified":"2016-05-23T23:54:58","modified_gmt":"2016-05-23T23:54:58","slug":"cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/","title":{"rendered":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen"},"content":{"rendered":"<p>AMB 2016, 50,\u00a035 Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen Fazit: Mit Cangrelor ist seit einigen Monaten ein durch intraven\u00f6se Infusion zu verabreichender und gut steuerbarer Thrombozytenaggregationshemmer verf\u00fcgbar. Wir sehen allenfalls f\u00fcr solche Patienten eine m\u00f6gliche Therapieoption, bei denen die Einnahme eines Thrombozytenaggregationshemmers (Clopidogrel, Ticagrelor oder Prasugrel) zus\u00e4tzlich zu ASS vor Einleitung einer perkutanen Koronarintervention nicht m\u00f6glich [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2016, 50,\u00a035 Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen Fazit: Mit Cangrelor ist seit einigen Monaten ein durch intraven\u00f6se Infusion zu verabreichender und gut steuerbarer Thrombozytenaggregationshemmer verf\u00fcgbar. Wir sehen allenfalls f\u00fcr solche Patienten eine m\u00f6gliche Therapieoption, bei denen die Einnahme eines Thrombozytenaggregationshemmers (Clopidogrel, Ticagrelor oder Prasugrel) zus\u00e4tzlich zu ASS vor Einleitung einer perkutanen Koronarintervention nicht m\u00f6glich [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[521,76,523,524,77,525,2377,2382,2381,2379,2380,2378,79,527,528,87,88,106],"class_list":["post-3652","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acbp","tag-angina-pectoris","tag-aortokoronarer-bypass","tag-aortokoronarer-venenbypass","tag-arteriosklerose","tag-bypass-operation","tag-cangrelor","tag-champion-bridge-studie","tag-champion-pci-studie","tag-champion-phoenix-studie","tag-champion-platform-studie","tag-champion-studie","tag-koronare-herzkrankheit","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-ptca","tag-thrombozytenaggregationshemmer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen<\/title>\n<meta name=\"description\" content=\"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen\" \/>\n<meta property=\"og:description\" content=\"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2016-05-23T23:54:58+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen\",\"datePublished\":\"2016-05-23T23:54:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/\"},\"wordCount\":290,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"ACBP\",\"Angina pectoris\",\"Aortokoronarer Bypass\",\"Aortokoronarer Venenbypass\",\"Arteriosklerose\",\"Bypass-Operation\",\"Cangrelor\",\"CHAMPION BRIDGE-Studie\",\"CHAMPION PCI-Studie\",\"CHAMPION PHOENIX-Studie\",\"CHAMPION PLATFORM-Studie\",\"CHAMPION-Studie\",\"Koronare Herzkrankheit\",\"PCI\",\"Perkutane Koronarintervention\",\"Perkutane transluminale koronare Angioplastie\",\"PTCA\",\"Thrombozytenaggregationshemmer\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/\",\"name\":\"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2016-05-23T23:54:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen","description":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/","og_locale":"de_DE","og_type":"article","og_title":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen","og_description":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2016-05-23T23:54:58+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen","datePublished":"2016-05-23T23:54:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/"},"wordCount":290,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["ACBP","Angina pectoris","Aortokoronarer Bypass","Aortokoronarer Venenbypass","Arteriosklerose","Bypass-Operation","Cangrelor","CHAMPION BRIDGE-Studie","CHAMPION PCI-Studie","CHAMPION PHOENIX-Studie","CHAMPION PLATFORM-Studie","CHAMPION-Studie","Koronare Herzkrankheit","PCI","Perkutane Koronarintervention","Perkutane transluminale koronare Angioplastie","PTCA","Thrombozytenaggregationshemmer"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/","name":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2016-05-23T23:54:58+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3652"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3652\/revisions"}],"predecessor-version":[{"id":3653,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3652\/revisions\/3653"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}